Research and Development of MSC1 and MSC2 Cell Therapy Products
First written in FY2020. 2 of 4 entries say "Advanced", first in FY2021. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「MSC2, which has potent anti-inflammatory activity, is expected to be developed as a treatment for inflammatory diseases, including optic neuritis, demyelinating diseases such as multiple sclerosis and Krabbe disease, diabetic neuropathy, rheumatoid arthritis and Crohn’s disease.」
The policy of developing MSC2 as a treatment for inflammatory diseases and the agreement with Ocumension concerning development and commercialization rights for optic neuritis in Greater China have been reconfirmed. - FY2022AdvancedAnnual report
「In November 2021, the Company also entered into a business partnership agreement with D&P Bioinnovations concerning the development and commercialization of an esophageal regeneration implant using MSC2 cells.」
A new partnership was established for the development and commercialization of an esophageal regeneration implant using MSC2 as part of the R&D of MSC1 and MSC2. - FY2021AdvancedAnnual report
「MSC2, which has potent anti-inflammatory activity, is expected to be developed as a treatment for inflammatory diseases, including optic neuritis, demyelinating diseases such as multiple sclerosis and Krabbe disease, diabetic neuropathy, rheumatoid arthritis and Crohn’s disease. In March 2020, the Company reached an agreement with Ocumension (Hong Kong) Limited concerning the development and commercialization rights in Greater China, including mainland China, Hong Kong, Macau and Taiwan, for a cell therapy product indicated for optic neuritis.」
In addition to the description of MSC2 as a development-stage drug candidate, specific progress was reported in the form of an agreement with Ocumension concerning development and commercialization rights for optic neuritis in Greater China. - FY2020First statedAnnual report
「In September 2018, the Company acquired from another company a patent portfolio relating to MSC1 and MSC2, mesenchymal stem cell-derived cell therapy products.」
It was first reported that the Company acquired the patent portfolio for MSC1 and MSC2 in September 2018 and was advancing preclinical studies, with MSC1 positioned as a cancer treatment and MSC2 as a treatment for inflammatory diseases.